Sigrid Therapeutics AB

STOCKHOLM, Jan. 21, 2026 /PRNewswire/ -- Sigrid Therapeutics (Sigrid) is a Swedish, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence, designed to reduce appetite and cravings while supporting fat loss, lean muscle preservation, and post-meal blood sugar control, and Glucose Stabiliser, a dietary supplement designed to help regulate blood sugar after meals — Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology platform into consumer oral health through a partner-led approach. "While our primary focus remains the continued commercialization of Carb Fence and Glucose Stabiliser , this partnership allows us to realize additional value from the SiPore® platform through a capital-efficient, non-dilutive approach," said Sana Alajmovic, Co-Founder and CEO of Sigrid. "It also demonstrates SiPore®'s potential to support multiple large-scale health applications over time and reflects strong validation of the platform following an extensive two-year scientific, technical, and commercial due diligence process conducted by a multinational partner." The agreement covers the use of SiPore® across consumer oral health formulations with the objective of enabling future commercialization following clinical validation. Under the terms of the agreement, Sigrid will receive upfront payment, development, clinical and sales-based milestones, and ongoing, long-term royalties on net sales. SiPore® is Sigrid's proprietary, non-systemic material technology platform built on precisely engineered porous silica particles. In oral health, SiPore® acts through a purely mechanical mode of action, binding and removing key proteins and enzymes involved in plaque and biofilm formation in the oral cavity. This enables an immediate and sustained first line of defense against plaque formation and dental caries, without systemic exposure. Oral diseases are the most common diseases globally, affecting an estimated 3.5 billion people worldwide. The global toothpaste market alone is valued at approximately USD 19 billion annually and is expected to grow to around USD 28 billion by 2034, driven by increasing focus on preventive health, premium formulations, and science-backed daily-use solutions. "Oral health is a demanding category where safety, efficacy, and daily usability are critical," said Damir Konakovic, Head of Oral Health at Sigrid. "This collaboration enables rigorous scientific validation of SiPore® in oral health, while leveraging a partner with the capabilities to translate that science into products that can reach consumers globally and at scale." Contact: Sana Alajmovic, Co-founder & CEO, SIGRID Therapeutics, [email protected] | +46 723 893 396 SOURCE Sigrid Therapeutics 21% more press release views with Request a Demo

STOCKHOLM, Nov. 3, 2025 /PRNewswire/ -- SIGRID, the Swedish innovative consumer care company behind the groundbreaking Glucose Stabiliser powered by patented SiPore® technology, today announced its expansion into the U.S. physician channel following a successful pilot program with selected integrative and functional medicine clinics. Continue Reading SIGRID Glucose Stabiliser As part of this initiative, SIGRID has partnered with an experienced industry insider to establish a dedicated sales infrastructure designed specifically for healthcare professionals and their businesses. This expansion marks a significant milestone in SIGRID's mission to advance metabolic health through innovative, science-backed solutions trusted by both consumers and practitioners. "Expanding into the physician channel is the next evolution for SIGRID," said Sana Alajmovic, Co-founder & CEO of SIGRID. "Physicians want patented, clinically proven tools that make a measurable difference for patients—and SiPore® is standing out as a solution they trust." Clinician Highlights from the Pilot Program bVital Center — Park City, Utah "At bVital, integrating Glucose Stabiliser into our precision protocols has dramatically improved our patients' glucose time-in-range — a measurable advance that's been pivotal in reducing neuroinflammation and supporting the body's innate healing capacity.", says Dr. Greg Eckel, founder of bVital. Full Circle Health — Edmond, Oklahoma "Glucose Stabiliser has transformed our patients' wellness journeys at Full Circle Health, empowering them to manage cravings, stabilize blood sugar, and embrace healthier digestion without invasive methods.", says Barbie Schrick, founder & Clinical Director, Full Circle Health. Partner With SIGRID Join the growing community of healthcare professionals and innovators partnering with SIGRID to deliver science-backed, patient-proven metabolic solutions. Learn more about partnership and white-label opportunities at: [email protected] Media Contact: Sana Alajmovic Co-founder & CEO, SIGRID [email protected] | +46 723 893 396 About SIGRID and Glucose Stabiliser With over 15 years of research, 10+ patents, and 6 clinical trials, SIGRID pioneers a non-pharmaceutical approach to blood sugar control and weight management. Glucose Stabiliser is a dietary supplement designed for health-conscious individuals seeking daily blood sugar balance and weight management support. Developed using SiPore® technology, Glucose Stabiliser slows the digestion of carbohydrates and fats, thus providing a convenient and effective solution for maintaining stable energy levels, lower body weight - while preserving muscle mass - and improving overall metabolic health. Read more at: Photo - Logo - SOURCE Sigrid Therapeutics 21% more press release views with Request a Demo

STOCKHOLM, March 10, 2025 /PRNewswire/ -- Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE study, the largest of its kind in prediabetes. Continue Reading Carb Fence™ stands out as the first clinically validated medical food specifically developed for prediabetes The study demonstrated that Carb Fence™, an medical-grade, fast-acting liquid formula powered by SiPore®, effectively reduces long-term blood sugar levels HbA1c (A1C), improves glucose metabolism, and reduces body weight - while preserving muscle mass. These robust findings position Carb Fence™ as a pioneering medical food in the U.S., a category recognized by the FDA for the dietary management of diseases or conditions under physician supervision, as defined by the Orphan Drug Act. With the U.S. medical food market experiencing rapid growth, Carb Fence™ stands out as the first clinically validated medical food specifically developed for prediabetes—a condition affecting one in three U.S. adults. "These achievements not only validate SiPore® as a safe, effective, and accessible solution to the diabetes and obesity crises but also position the platform for growth across multiple industries", says Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics. The SHINE study1, a double-blind, placebo-controlled, randomized trial, aimed to assess the safety and tolerability of SiPore®-powered Carb Fence™ while confirming its efficacy across key metabolic markers. The SHINE study, a randomized, placebo-controlled trial, enrolled 318 participants with elevated blood sugar levels and excess body weight and was conducted across 27 clinics in three European countries. Carb Fence™ significantly reduced A1C from baseline in both males and females. The female group achieved a clinically relevant, statistically significant, placebo-adjusted reduction, providing strong evidence of the product's mechanism of action. While males experienced comparable, clinically meaningful A1C reductions, statistical significance versus placebo was not reached due to a stronger placebo response—an occurrence well-documented in clinical research.2 Notably, many participants in the male placebo group showed significant improvements in liver health, likely due to reduced alcohol consumption. This suggests unintended lifestyle changes, despite instructions to maintain their usual habits. Excluding participants with substantial liver health improvements from the analysis eliminated the placebo effect on A1C. Contact: Sana Alajmovic, C-founder & CEO, Sigrid Therapeutics, [email protected] For more information: Link to full press release 1 2 Vambheim SM, Flaten MA. A systematic review of sex differences in the placebo and the nocebo effect. J Pain Res. 2017 Jul 31;10:1831-1839. Photo - Logo - SOURCE Sigrid Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED